Company News • Endpoint Arena

News Updates

Tue, May 26, 2026

1 updates

8:00 AM

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - - Humacyte anticipates that top-line interim

Interim Data • Phase 3V012 Phase 3 interim results Thu, Jun 11, 2026humacyte.com

Wed, May 20, 2026

1 updates

HUMA

8:00 AM

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals - DURHAM, N.C., May 20, 2026 (GLOBE

humacyte.com

Wed, May 13, 2026

1 updates

HUMA

7:00 AM

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and

Interim Data • Phase 3V012 Phase 3 interim results at SVS VAM Thu, Jun 11, 2026humacyte.com

Tue, May 12, 2026

1 updates

HUMA

8:00 AM

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer - - Appointment brings important surgical experience and perspective to Humacyte’s corporate leadership team as clinical adoption of Symvess® ramps up

humacyte.com

Fri, May 8, 2026

1 updates

HUMA

8:00 AM

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter

humacyte.com

Mon, Apr 27, 2026

1 updates

HUMA

8:00 AM

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host a virtual key opinion leader (KOL) event on

Results Call • Phase 3Call Tue, Apr 28, 2026, 8:00 AM EThumacyte.com

Fri, Apr 24, 2026

1 updates

HUMA

8:00 AM

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

- Ex- U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding international and indication-specific rights to Symvess – - Existing terms related to U.S.

humacyte.com

Wed, Apr 22, 2026

1 updates

HUMA

8:00 AM

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and cardiothoracic surgery markets – – Appointment strengthens commercial leadership as

humacyte.com

Tue, Apr 21, 2026

1 updates

HUMA

8:00 AM

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology

humacyte.com

Fri, Mar 27, 2026

1 updates

HUMA

7:00 AM

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing

Interim Data • Phase 3humacyte.com

Thu, Mar 26, 2026

1 updates

HUMA

8:00 AM

Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - - He will work with the Company’s leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte’s broad pipeline

humacyte.com

Mon, Mar 23, 2026

1 updates

HUMA

8:00 AM

Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter

humacyte.com

Thu, Mar 19, 2026

2 updates

HUMA

8:31 AM

Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia

- Purchase commitment is for a minimum of $1.475 million of Symvess product - DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today

humacyte.com

HUMA

8:30 AM

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis The offering was led by a new life science dedicated investor and a long-only

humacyte.com

Tue, Mar 17, 2026

1 updates

HUMA

8:00 AM

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - Preparation is underway for expansion of Symvess into other countries, including in the Middle East - DURHAM, N.C., March 17, 2026 (GLOBE NEWSWIRE) --

humacyte.com